Search

Your search keyword '"Gedde‐Dahl, Tobias"' showing total 22 results
Start Over Author "Gedde‐Dahl, Tobias" Search Limiters Peer Reviewed Publication Year Range This year Language english
22 results on '"Gedde‐Dahl, Tobias"'

1. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Guièze, Romain, Eikema, Diderik-Jan, Koster, Linda, Schetelig, Johannes, Sengeloev, Henrik, Passweg, Jakob, Finke, Jürgen, Arat, Mutlu, Broers, Annoek E. C., Stölzel, Friedrich, Byrne, Jenny, Castilla-Llorente, Cristina, Dreger, Peter, Eder, Matthias, Gedde-Dahl, Tobias, Kröger, Nicolaus, Ribera Santasusana, Josep Maria, Richardson, Deborah, Rambaldi, Alessandro, Yañez, Lucrecia, Van Gelder, Michel, Drozd-Sokolowska, Joanna, Raj, Kavita, Yakoub-Agha, Ibrahim, Tournilhac, Olivier, and McLornan, Donal P.

Published
2024
Full Text
View/download PDF

2. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Nagler, Arnon, Labopin, Myriam, Swoboda, Ryszard, Schroeder, Thomas, Hamladji, Rose-Marie, Griskevicius, Laimonas, Salmenniemi, Urpu, Rambaldi, Alessandro, Mielke, Stephan, Kulagin, Alexander, Passweg, Jakob, Luft, Thomas, Gedde-Dahl, Tobias, Forcade, Edouard, Helbig, Grzegorz, Stelljes, Matthias, Castilla-Llorente, Cristina, Spyridonidis, Alexandros, Brissot, Eolia, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

3. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

Author

Penack, Olaf, Abouqateb, Mouad, Peczynski, Christophe, Boreland, William, Kröger, Nicolaus, Stelljes, Matthias, Gedde-Dahl, Tobias, Blau, Igor Wolfgang, Schroeder, Thomas, Salmenniemi, Urpu, Kulagin, Alexander, Peffault de Latour, Régis, Mielke, Stephan, Zeiser, Robert, Moiseev, Ivan, Schoemans, Hélène, Koenecke, Christian, and Peric, Zinaida

Published
2024
Full Text
View/download PDF

4. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

Author

Flygt, Hjalmar, Söderlund, Stina, Richter, Johan, Saussele, Susanne, Koskenvesa, Perttu, Stenke, Leif, Mustjoki, Satu, Dimitrijevic, Andreja, Stentoft, Jesper, Majeed, Waleed, Roy, Lydia, Wolf, Dominik, Dreimane, Arta, Gjertsen, Bjørn Tore, Gedde-Dahl, Tobias, Ahlstrand, Erik, Markevärn, Berit, Hjorth-Hansen, Henrik, Janssen, Jeroen, and Olsson-Strömberg, Ulla

Published
2024
Full Text
View/download PDF

6. The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party

Author

Gjærde, Lars Klingen, Ruutu, Tapani, Peczynski, Christophe, Boreland, William, Kröger, Nicolaus, Blaise, Didier, Schroeder, Thomas, Peffault de Latour, Régis, Gedde-Dahl, Tobias, Kulagin, Aleksandr, Sengeløv, Henrik, Yakoub-Agha, Ibrahim, Finke, Jürgen, Eder, Matthias, Basak, Grzegorz, Moiseev, Ivan, Schoemans, Hélène, Koenecke, Christian, Penack, Olaf, and Perić, Zinaida

Published
2024
Full Text
View/download PDF

7. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Author

Spyridonidis, Alexandros, Labopin, Myriam, Gedde-Dahl, Tobias, Ganser, Arnold, Stelljes, Matthias, Craddock, Charles, Wagner-Drouet, Eva Maria, Versluis, Jurjen, Schroeder, Thomas, Blau, Igor Wolfgang, Wulf, Gerald. G., Dreger, Peter, Olesen, Gitte, Sengeloev, Henrik, Kröger, Nicolaus, Potter, Victoria, Forcade, Edouard, Passweg, Jakob, de Latour, Régis Peffault, Maertens, Johan, Wilson, Keith M. O., Bourhis, Jean Henri, Finke, Juergen, Brissot, Eolia, Bazarbachi, Ali, Giebel, Sebastian, Savani, Bipin P., Nagler, Arnon, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

8. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms

Author

Chalandon, Yves, Eikema, Diderik-Jan, Moiseev, Ivan, Ciceri, Fabio, Koster, Linda, Vydra, Jan, Passweg, Jakob, Rovira, Montserrat, Ozcelik, Tulay, Gedde-Dahl, Tobias, Kröger, Nicolaus, Potter, Victoria, Yakoub-Agha, Ibrahim, Rambaldi, Alessandro, Itälä-Remes, Maija, Tanase, Alina, Onida, Francesco, Gurnari, Carmelo, Scheid, Christof, Drozd-Sokolowska, Joanna, Raj, Kavita, McLornan, Donal P., and Robin, Marie

Published
2024
Full Text
View/download PDF

10. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Author

Scheid, Christof, Eikema, Diderik-Jan, van Gelder, Michel, Salmenniemi, Urpu, Maertens, Johan, Passweg, Jakob, Blaise, Didier, Byrne, Jennifer L., Kröger, Nicolaus, Sockel, Katja, Chevallier, Patrice, Bourhis, Jean Henri, Cornelissen, Jan J., Sengeloev, Henrik, Finke, Jürgen, Snowden, John A., Gedde-Dahl, Tobias, Cornillon, Jérôme, Schanz, Urs, Patel, Amit, Koster, Linda, de Wreede, Liesbeth C., Hayden, Patrick, Raj, Kavita, Drozd-Sokolowska, Joanna, Gurnari, Carmelo, Onida, Francesco, McLornan, Donal P., Robin, Marie, and Yakoub-Agha, Ibrahim

Published
2024
Full Text
View/download PDF

11. Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Author

Montoro, Juan, Eikema, Dirk-Jan, Tuffnell, Joe, Potter, Victoria, Kalwak, Krzysztof, Halkes, Constantijn J. M., Kulagin, Alexander, Collin, Matthew, Wynn, Robert F., Robinson, Stephen, Nicholson, Emma, Sengeloev, Henrik, Clay, Jennifer, Halahleh, Khalid, Skorobogatova, Elena, Sanz, Jaime, Passweg, Jakob, Mielke, Stephan, Ryhänen, Samppa, Carpenter, Ben, Gedde-Dahl, Tobias, Tholouli, Eleni, Fanin, Renato, Lewalle, Philippe, Kulasekararaj, Austin, Risitano, Antonio, and Peffault de Latour, Régis

Published
2024
Full Text
View/download PDF

13. Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, Labopin, Myriam, Peric, Zinaida, Passweg, Jakob, Blaise, Didier, Salmenniemi, Urpu, Beauvais, David, Reményi, Péter, Chevallier, Patrice, Mielke, Stephan, Gedde-Dahl, Tobias, Cornelissen, Jan J., Balsat, Marie, Bug, Gesine, Bazarbachi, Ali, Brissot, Eolia, Nagler, Arnon, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

14. Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies.

Author

Arrieta-Bolaños, Esteban, Bonneville, Edouard F., Crivello, Pietro, Robin, Marie, Gedde-Dahl, Tobias, Salmenniemi, Urpu, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, Crawley, Charles, Choi, Goda, Broers, Annoek E.C., Forcade, Edouard, Carre, Martin, Poiré, Xavier, Huynh, Anne, Lenhoff, Stig, Ciceri, Fabio, Tholouli, Eleni, Schroeder, Thomas, and Deconinck, Eric

Published
2024
Full Text
View/download PDF

15. Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post‐transplant cyclophosphamide versus conventional anti‐graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Nagler, Arnon, Ngoya, Maud, Galimard, Jacques‐Emmanuel, Labopin, Myriam, Blau, Igor Wolfgang, Kröger, Nicolaus, Gedde‐Dahl, Tobias, Schroeder, Thomas, Burns, David, Salmenniemi, Urpu, Rambaldi, Alessandro, Choi, Goda, Peffault de Latour, Régis, Vydra, Jan, Sengeloev, Henrik, Eder, Matthias, Mielke, Stephan, Forcade, Edouard, Kulagin, Alexander, and Ciceri, Fabio

Published
2024
Full Text
View/download PDF

16. Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study

Author

Loke, Justin, Labopin, Myriam, Craddock, Charles, Socié, Gérard, Gedde‐Dahl, Tobias, Blaise, Didier, Forcade, Edouard, Salmenniemi, Urpu, Huynh, Anne, Versluis, Jurjen, Yakoub‐Agha, Ibrahim, Labussière‐Wallet, Hélène, Maertens, Johan, Passweg, Jakob, Bulabois, Claude Eric, Gabellier, Ludovic, Mielke, Stephan, Castilla‐Llorente, Cristina, Deconinck, Eric, and Brissot, Eolia

Subjects
ACUTE myeloid leukemia, ACUTE leukemia, STEM cell transplantation, LEUCOCYTES, BONE marrow
Abstract

Introduction: For the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission. Methods: This Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)‐matched unrelated donor (HLA‐A, HLA‐B, HLA‐C, HLA‐DR, or HLA‐DQ). Univariate and multivariate analyses were undertaken to identify the prognostic impact of one or two courses of induction to attain CR. Results: A total of 4995 patients were included with 3839 (77%) patients attaining a CR following one course of induction chemotherapy (IND1), and 1116 patients requiring two courses (IND2) to attain CR. IND2 as compared to IND1 was a poor prognostic factor in a univariate analysis and remained so in a multivariate Cox model, resulting in an increased hazard ratio of relapse (1.38; 95% confidence interval [CI], 1.16–1.64; p =.0003) and of death (1.27; 95% CI, 1.09–1.47; p =.002). Adverse prognostic factors in a multivariate analysis of the outcomes of patients requiring IND2 included age, FLT3‐ITD, adverse cytogenetics, and performance status. Pretransplant measurable residual disease retained a prognostic impact regardless of IND1 or IND2. Conclusion: Initial response to chemotherapy as determined by number of courses to attain CR, retained prognostic relevance even following SCT in CR. Patients requiring two courses of induction to attain complete remission (CR) have a higher incidence of relapse and inferior survival as compared to those who require one course. Pretransplant measurable residual disease remains important in predicting outcomes following an allogeneic stem cell transplant in those requiring two courses of induction to achieve CR. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Ye, Yishan, Labopin, Myriam, Gérard, Socié, Yakoub‐Agha, Ibrahim, Blau, Igor Wolfgang, Aljurf, Mahmoud, Forcade, Edouard, Gedde‐Dahl, Tobias, Burns, David, Vydra, Jan, Halahleh, Khalid, Hamladji, Rose‐Marie, Bazarbachi, Ali, Nagler, Arnon, Brissot, Eolia, Li, Lin, Luo, Yi, Zhao, Yanmin, Ciceri, Fabio, and Huang, He

Published
2024
Full Text
View/download PDF

18. The function of the complement system remains fully intact throughout the course of allogeneic stem cell transplantation.

Author

Fageräng, Beatrice, Cyranka, Leon, Schjalm, Camilla, McAdam, Karin Ekholt, Larsen, Carina Sandem, Heinzelbecker, Julia, Gedde-Dahl, Tobias, Würzner, Reinhard, Espevik, Terje, Tjønnfjord, Geir Erland, Garred, Peter, Barratt-Due, Andreas, Tvedt, Tor Henrik Anderson, and Mollnes, Tom Eirik

Subjects
STEM cell transplantation, COMPLEMENT activation, HEMATOPOIETIC stem cell transplantation, COMPLEMENT (Immunology), ACUTE myeloid leukemia, COMPLEMENT inhibition
Abstract

Introduction: Hematopoietic stem cell transplantation (HSCT) is associated with immune complications and endothelial dysfunction due to intricate donorrecipient interactions, conditioning regimens, and inflammatory responses. Methods: This study investigated the role of the complement system during HSCT and its interaction with the cytokine network. Seventeen acute myeloid leukemia patients undergoing HSCT were monitored, including blood sampling from the start of the conditioning regimen until four weeks post-transplant. Clinical follow-up was 200 days. Results: Total complement functional activity was measured by WIELISA and the degree of complement activation by ELISA measurement of sC5b-9. Cytokine release was measured using a 27-multiplex immuno-assay. At all time-points during HSCT complement functional activity remained comparable to healthy controls. Complement activation was continuously stable except for two patients demonstrating increased activation, consistent with severe endotheliopathy and infections. In vitro experiments with post-HSCT whole blood challenged with Escherichia coli, revealed a hyperinflammatory cytokine response with increased TNF, IL-1b, IL-6 and IL-8 formation. Complement C3 inhibition markedly reduced the cytokine response induced by Staphylococcus aureus, Aspergillus fumigatus, and cholesterol crystals. Discussion: In conclusion, HSCT patients generally retained a fully functional complement system, whereas activation occurred in patients with severe complications. The complement-cytokine interaction indicates the potential for new complement-targeting therapeutic strategies in HSCT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Epigenetic aging of human blood cells is influenced by the age of the host body.

Author

Holland, Petter, Istre, Mette, Ali, Maryan M., Gedde‐Dahl, Tobias, Buechner, Jochen, Wildhagen, Mari, Brunvoll, Sonja H., Horvath, Steve, Matsuyama, Shigemi, Dahl, John Arne, Stölzel, Friedrich, and Søraas, Arne

Subjects
HEMATOPOIETIC stem cell transplantation, BLOOD cells, AGING, EPIGENETICS, CELLULAR aging
Abstract

Allogenic hematopoietic stem cell transplantation is a therapeutic procedure performed over a wide range of donor and recipient age combinations, representing natural experiments of how the age of the recipient affects aging in transplanted donor cells in vivo. We measured DNA methylation and epigenetic aging in donors and recipients and found that biological epigenetic clocks are accelerated in cells transplanted into an older body and decelerated in a younger body. This is the first evidence that the age of the circulating environment influences human epigenetic aging in vivo. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.

Author

Penack, Olaf, Abouqateb, Mouad, Peczynski, Christophe, Boreland, William, Gülbas, Zafer, Gedde-Dahl, Tobias, Castilla-Llorente, Cristina, Kröger, Nicolaus, Eder, Mathias, Rambaldi, Alessandro, Bonifazi, Francesca, Blau, Igor Wolfgang, Stelljes, Matthias, Dreger, Peter, Moiseev, Ivan, Schoemans, Hélène, Koenecke, Christian, and Peric, Zinaida

Subjects
STEM cell transplantation, GRAFT versus host disease, PREVENTIVE medicine, OVERALL survival, PROGRESSION-free survival
Abstract

There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing clinical use. It is currently impossible to give general recommendations regarding preference for one method over another since comparative evidence from larger data sets is lacking. To improve the evidence base, we analyzed the outcome of rATG vs. PTCy prophylaxis in adult patients with hematologic malignancies undergoing first peripheral blood alloSCT from MMUD (9/10 antigen match) between Jan 2018 and June 2021 in the database of the European Society for Blood and Marrow Transplantation (EBMT). We performed multivariate analyses using the Cox proportional-hazards regression model. We included 2123 patients in the final analyses (PTCy, n = 583; rATG, n = 1540). p values and hazard ratios (HR) presented here are multivariate outcomes. Two years after alloSCT we found a lower NRM in the PTCy group of 18% vs. 24.9% in the rATG group; p = 0.028, HR 0.74. Overall survival in the PTCy cohort was higher with 65.7% vs. 55.7% in the rATG cohort; p < 0.001, HR 0.77. Progression-free survival was also better in the PTCy patients with 59.1% vs. 48.8% when using rATG; p = 0.001, 0.78. The incidences of chronic GVHD and acute GVHD were not significantly different between the groups. We found significantly lower NRM as well as higher survival in recipients of peripheral blood alloSCTs from MMUD receiving PTCy as compared to rATG. The results of the current analysis suggest an added value of PTCy as GVHD prophylaxis in MMUD alloSCT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1‐mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Author

Moukalled, Nour, Labopin, Myriam, Versluis, Jurjen, Socié, Gérard, Blaise, Didier, Salmenniemi, Urpu, Rambaldi, Alessandro, Gedde‐Dahl, Tobias, Tholouli, Eleni, Kröger, Nicolaus, Bourhis, Jean‐Henri, Von Dem Borne, Peter, Daguindau, Etienne, Forcade, Edouard, Nagler, Arnon, Esteve, Jordi, Ciceri, Fabio, Bazarbachi, Ali, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results